These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26117057)

  • 1. [Association of CRBN Gene with Immunomodulatory Drug Resis- tance in Multiple Myeloma].
    Cai QQ; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):892-7. PubMed ID: 26117057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
    Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients.
    Barankiewicz J; Szumera-Ciećkiewicz A; Salomon-Perzyński A; Wieszczy P; Malenda A; Garbicz F; Prochorec-Sobieszek M; Misiewicz-Krzemińska I; Juszczyński P; Lech-Marańda E
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34207079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma.
    Chen LY; Gooding S
    Front Oncol; 2022; 12():1038329. PubMed ID: 36439455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
    An R; Hou J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
    Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
    J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
    Bedewy AM; El-Maghraby SM
    Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
    Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
    Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of cereblon levels by anti-myeloma agents.
    Díaz-Rodríguez E; Pandiella A
    Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
    Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
    Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling.
    Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ
    Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMiD compounds affect CD34
    Li S; Fu J; Wang H; Ma H; Xu X; Yang YG; Deng S; Mapara MY; Lentzsch S
    Blood Adv; 2018 Mar; 2(5):492-504. PubMed ID: 29496670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.